AMP Adds to Lipocine Position and Starts Position in Cara Therapeutics for Hypothetical Fund


This past week AMP increased it's position in Lipocine Inc. (LPCN) by adding an additional 6,964 shares at $3.59/share. This transaction doubles AMP's position in LPCN bringing it up to $50K in invested funds.

AMP also started a position in Cara Therapeutics (CARA) by purchasing 1,258 shares at $19.88/share for a transaction totaling ~$25K. Cara Therapeutics is a clinical-stage located in Stamford, CT developing and commercializing new chemical entities designed to change the way acute pain, chronic pain and pruritus are managed.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon